アルツハイマー病（AD）患者におけるガンテネルマブの長期投与の安全性および忍容性を評価する研究

基本情報

NCT ID

NCT04339413

ステータス

中止

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

116

治験依頼者名

Hoffmann-La Roche

概要

The main purpose of the study was to evaluate the safety and tolerability of long-term administration of gantenerumab in participants with AD. All participants who have completed the open-label extensions (OLEs) of studies WN25203 or WN28745 were enrolled in Part 1 of this study. Of these, participants who completed Week 104 visit in Part 1. Participants received open-label gantenerumab by subcutaneous (SC) injection every four weeks (Q4W) at the same dose as administered in the parent studies (part 1)/ Week 104 visit.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)